How standard is second-line cetuximab in recurrent or metastatic head and neck cancer in 2017?

Petr Szturz; Tanguy Y. Seiwert; Jan B. Vermorken

doi:10.1200/JCO.2016.71.8072

How standard is second-line cetuximab in recurrent or metastatic head and neck cancer in 2017?

Petr Szturz, Tanguy Y. Seiwert, Jan B. Vermorken

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	2229-2231
Number of pages	3
Journal	Journal of Clinical Oncology
Volume	35
Issue number	20
DOIs	https://doi.org/10.1200/JCO.2016.71.8072
State	Published - Jul 10 2017
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.2016.71.8072

Cite this

@article{73678f631e2f438bae2b19546dfa269b,

title = "How standard is second-line cetuximab in recurrent or metastatic head and neck cancer in 2017?",

author = "Petr Szturz and Seiwert, {Tanguy Y.} and Vermorken, {Jan B.}",

year = "2017",

month = jul,

day = "10",

doi = "10.1200/JCO.2016.71.8072",

language = "English (US)",

volume = "35",

pages = "2229--2231",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",